Company news
CSPC Pharmaceutical Group Limited news in 2021
CSPC Pharmaceutical Group Limited's news releases, calls and decks from 2021, newest first.
CSPC Pharmaceutical Group: Voluntary announcement - "oseltamivir phosphate capsules" obtains drug registration approval
September 1, 2021
CSPC Pharmaceutical Group: Voluntary announcement - "alogliptin benzoate tablets" obtains drug registration approval
May 12, 2021
CSPC Pharmaceutical Group: Voluntary announcement - "sorafenib tosylate tablets" obtains drug registration approval
May 12, 2021
Voluntary announcement - passing of consistency evaluation for "doxorubicin hydrochloride liposome injection"
May 12, 2021
CSPC Pharmaceutical Group: Voluntary announcement - "sitagliptin phosphate tablets" obtains drug registration approval
May 12, 2021
Voluntary announcement - investigational first-in-class product SYSA1801 granted orphan-drug designation by the U.S. FDA
May 6, 2021
CSPC Pharmaceutical Group: Connected transaction - disposal of 49.5% equity interest in joint venture company /continuing connected transactions - master purchase agreement
April 30, 2021
Inside information - principal financial information of cspc innovation pharmaceutical co., ltd. for the three months ended 31 March 2021
April 26, 2021
CSPC Pharmaceutical Group: Voluntary announcement - nbl-012 obtains clinical trial approval in china
April 23, 2021
Voluntary announcement - application for marketing approval of "duvelisib capsules" accepted by nmpa
April 19, 2021
CSPC Pharmaceutical Group: Proposals for general mandates to buy-back shares and to issue shares and mandate to grant options, re-election of the retiring directors, and notice of annual general meeting
April 14, 2021
Investigational new drug nbl-015 granted orphan-drug designation by the U.S. FDA
April 9, 2021
Voluntary announcement - "amphotericin b cholesteryl sulfate complex for injection" obtains drug registration approval
April 1, 2021
Voluntary announcement - first patient dosed in phase i clinical trial of "docetaxel for injection (albumin-bound)"
March 30, 2021
CSPC Pharmaceutical Group: Voluntary announcement - JMT601 obtains clinical trial approval in the U.S.
March 29, 2021
CSPC Pharmaceutical Group: Voluntary announcement - JMT601 obtains clinical trial approval in china
March 25, 2021
Annual results for the year ended 31 December 2020
March 15, 2021
Voluntary announcement - product licensing and commercialization agreement
March 9, 2021
Appointment and resignation of independent non-executive directors
March 5, 2021
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 December 2020
March 4, 2021